Evamist
NDC Package 64011-215-42

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Evamist is a medication a female hormone (estrogen). Marketed by Amag Pharmaceuticals, Inc., this product is identified by NDC 64011-215 and is authorized under FDA application NDA022014.

Identification & Billing

NDC Package Code
64011-215-42
Package Description
56 SPRAY, METERED in 1 VIAL, MULTI-DOSE
Product Code
11-Digit Billing Format
64011021542

Clinical Specifications

Proprietary Name
Evamist
Dosage Form
-
Usage Information
This medication is a female hormone (estrogen). It is absorbed through the skin and enters into the bloodstream. It is used by women to help reduce a certain symptom of menopause (hot flashes). Symptoms of menopause are caused by the body making less estrogen. If you are using estrogens to treat only vaginal symptoms of menopause (such as vaginal dryness/burning/itching), products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected.

Regulatory & Marketing

Labeler Name
Amag Pharmaceuticals, Inc.
FDA Application #
NDA022014
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-08-2009
End Marketing Date
12-31-2017
Listing Expiration
12-31-2017
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (64011-215). Click a package code to view its specific billing and regulatory data.

56 SPRAY, METERED in 1 VIAL, MULTI-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 64011-215-42 identifies a specific commercial package of 56 spray, metered in 1 vial, multi-dose of Evamist, labeled by Amag Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Amag Pharmaceuticals, Inc. on July 08, 2009. The current certification is valid through December 31, 2017.

What are the primary indications for this medication?

This medication is a female hormone (estrogen). It is absorbed through the skin and enters into the bloodstream. It is used by women to help reduce a certain symptom of menopause (hot flashes). Symptoms of menopause are caused by the body making less estrogen. If you are using estrogens to treat only vaginal symptoms of menopause (such as vaginal dryness/burning/itching), products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected.

How is this Amag Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 64011021542. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
64011-215-42
11-Digit CMS (5-4-2)
64011-0215-42

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.